Arkema Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Arkema
Actionable Strategy Starts Here
Arkema’s preliminary BCG Matrix snapshot highlights where key product lines sit amid shifting demand and competitive intensity—some promising Stars, several stable Cash Cows, and potential Question Marks worth watching—offering a concise view of resource needs and growth prospects. This preview teases strategic signals; purchase the full BCG Matrix to receive quadrant-by-quadrant placements, data-driven recommendations, and ready-to-use Word and Excel files that help you prioritize investments, divest non-core units, and drive profitable portfolio decisions.
Stars
Bio-sourced Polyamides
Arkema holds a dominant share in high-performance bio-based polyamides via Rilsan Polyamide 11, supplying ~40% of the global PA11 market in 2025 and key EV thermal-management and high-end electronics supply chains.
Demand grew ~18% CAGR 2022–25, driven by EV adoption; Arkema reported €1.1bn PA11-related sales in 2024 and is investing €200–300m to expand capacity through 2026.
PVDF for Electric Vehicle Batteries
Kynar PVDF is a star in Arkema’s BCG matrix: market-leading electrode binders and separator coatings for lithium-ion batteries, with EV battery demand growing ~25% CAGR 2023–2028 and PVDF volumes up ~30% in 2024.
Arkema’s tech lead and 2024 capex—about €150–200m invested in North America and Asia—supports scale-up to meet projected 60–80 kt PVDF demand by 2028 amid rising competition.
Performance Adhesives for Electronics
Performance Adhesives for Electronics sit in Arkema’s BCG Stars: Bostik’s electronics adhesives grew ~12% CAGR 2020–2024, serving a $4.5B global miniaturized-electronics adhesives market (2024, Freedonia).
High R&D intensity—Arkema spent €135M on Adhesive Solutions in 2024—matches rapid device cycles, keeping share gains and margin expansion prospects strong.
Advanced Composites for Aerospace
Arkema’s Elium liquid thermoplastic and Kepstan PEKK drive lightweight, recyclable aircraft parts; Elium enables faster out-of-autoclave processing and Kepstan offers 20–30% better heat resistance vs PEEK, matching OEM decarbonization targets as aerospace demand rose ~18% in 2024 after COVID lows.
High technical barriers, ~€200m+ annual R&D investments across specialty polymers in 2024, and long qualification cycles let Arkema hold a leading niche; market forecasts project 6–8% CAGR through 2030 for aerospace composites, placing this business in the BCG Matrix’s Star quadrant.
- Elium: recyclable thermoplastic for fast production
- Kepstan PEKK: high-temp, durable polymer
- Aerospace demand +18% in 2024; composites CAGR 6–8% to 2030
- Arkema R&D ~€200m+ (2024), strong technical moat
Sartomer High-End Photocurable Resins
Sartomer high-end photocurable resins lead specialty UV/EB curing markets, powering high-resolution printing and advanced sustainable-packaging coatings; Arkema reported Sartomer sales of ~€450M in 2024, with segment growth ~8% YoY and end-market CAGR ~9% (2024–2027 estimates).
Competition is rising, but Arkema’s portfolio of 1,200+ patents and global technical service centers (30+ labs) sustain market leadership and gross margins above 28% in this business.
- Market share: ~22% global specialty photocurable resins
- 2024 Sartomer sales: ~€450M; growth ~8% YoY
- Patent assets: 1,200+; tech centers: 30+
- Business gross margin: >28%; end-market CAGR: ~9% (2024–2027)
Arkema growth engines: PA11 dominance, PVDF scale-up, Elium niche & Sartomer strength
Arkema’s Stars: PA11 (Rilsan) ~40% global share; €1.1bn sales (2024); 18% CAGR 2022–25; €200–300m capex to 2026. PVDF (Kynar) scaling to 60–80 kt by 2028; 30% volume growth (2024); €150–200m 2024 capex. Elium/Kepstan aerospace niche, 6–8% composites CAGR to 2030; Sartomer €450M sales (2024), ~22% market share.
| Product | 2024 sales/size | Share/vol | Growth/CAGR | Capex/R&D |
|---|---|---|---|---|
| Rilsan PA11 | €1.1bn | ~40% | 18% (2022–25) | €200–300m to 2026 |
| Kynar PVDF | — | 60–80 kt by 2028 | 30% vol (2024) | €150–200m (2024) |
| Elium/Kepstan | — | niche | 6–8% comps to 2030 | €200m+ R&D (2024) |
| Sartomer | €450M | ~22% | ~8% YoY (2024) | 1,200+ patents; 30+ labs |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Arkema’s portfolio with strategic guidance on Stars, Cash Cows, Question Marks and Dogs.
Customizable Excel Spreadsheet
One-page Arkema BCG Matrix placing each business unit in a quadrant for quick strategic clarity
Cash Cows
Bostik Construction and DIY Adhesives
Bostik Construction and DIY adhesives deliver steady cash flow for Arkema, with Bostik holding roughly 25%–30% share of the global mature construction-adhesives market and generating an estimated €700–€850m in annual sales in 2024.
These products need relatively low marketing spend versus Arkema’s high-tech segments and leverage an extensive retail and pro distribution network spanning 100+ countries.
Stable renovation and infrastructure maintenance demand—about €400bn annual EU construction maintenance spend as of 2023—provides predictable cash to fund Arkema’s R&D and specialty-materials growth bets.
Decorative Coating Resins
Arkema's decorative coating resins compete in a mature global paint market growing ~2% CAGR 2020–2024; demand is stable and regional paint volumes recovered to 2019 levels by 2023 per IHS Markit.
As a market leader, Arkema emphasizes operational excellence and cost optimization—its Coating Resins EBITDA margin for 2024 estimated ~18–22%, above group average, driving cash generation.
These resins supplied consistent free cash flow in 2024, helping Arkema pay a €1.15 dividend per share in 2024 and cut net debt by ~€400m year-on-year, supporting balance-sheet strength.
Industrial Specialty Additives
The industrial specialty additives segment, covering rheology modifiers and processing aids, serves mature markets—construction, coatings, adhesives—where Arkema held an estimated 2024 revenue share of ~€650m within Performance Products, providing roughly 12% of group EBITDA in 2024.
Products are embedded in customer processes, creating high switching costs; typical contract renewal rates exceed 85% and gross margins run near 32%, making this a stable cash cow.
Market growth averages 1–2% annually, so these additives generate strong free cash flow with low capex intensity (~3% of segment sales), needing minimal reinvestment.
Kynar PVDF for Chemical Processing
Kynar PVDF for chemical processing is a cash cow: mature, low-growth but high-margin, with Arkema recording PVDF segment EBITDA margins near 25% in 2024 and steady annual sales ~€220m for industrial piping and linings.
Customers pay premiums for decades-proven chemical resistance; installed-base replacement cycles of 10–20 years deliver predictable cash flow and >€50m free cash annually tied to Kynar industrial products.
- Established brand: Kynar >40 years in piping
- 2024 sales ≈ €220m; EBITDA margin ≈ 25%
- Installed-base cycles 10–20 years
- Predictable FCF >€50m annually
Specialty Surfactants for Agrochemicals
Arkema’s specialty surfactants for agrochemicals sit in Cash Cows: steady global crop protection demand (global crop protection market ~$70B in 2024) supports ~3–5% annual volume growth; Arkema holds an estimated double-digit share in targeted niches, supplying major agrochemical firms with bespoke formulations.
Unit runs high-margin operations with EBITDA margins above 18% in 2024 and low incremental CAPEX (under 2% of sales), sustaining cash generation and funding R&D for formulation tweaks.
- Market tailwind: global crop protection ~$70B (2024)
- Arkema share: estimated double-digit in specialty agro niches
- EBITDA: >18% (2024)
- CAPEX intensity: <2% of sales
- Status: Cash Cow — high cash, low reinvestment
Arkema’s 2024 cash cows: €1.9–2.1bn sales, €350–420m EBITDA funding payouts
Bostik construction adhesives, coating resins, specialty additives, Kynar PVDF, and specialty agro surfactants acted as Arkema cash cows in 2024, collectively generating ~€1.9–2.1bn sales and ~€350–420m EBITDA, funding dividends and net-debt reduction.
| Product | 2024 Sales | EBITDA % | FCF |
|---|---|---|---|
| Bostik adhesives | €700–850m | — | — |
| Coating resins | — | 18–22% | — |
| Specialty additives | €650m | ~32% | — |
| Kynar PVDF | €220m | ~25% | €50m+ |
| Agro surfactants | — | >18% | — |
What You’re Viewing Is Included
Arkema BCG Matrix
The file you're previewing on this page is the exact Arkema BCG Matrix report you'll receive after purchase—no watermarks, no placeholders, just the fully formatted, analysis-ready document crafted for strategic clarity and professional use.
Dogs
Legacy High-GWP Fluorogases
Legacy high-GWP fluorogases face EU F-gas Regulation cuts of ~79% by 2030 vs 2015 and US EPA SNAP phase-downs, driving demand down ~40% in refrigerant volumes since 2015.
These products hold low market share for Arkema—estimated <5% of specialty gases revenue in 2024—and sit in a contracting segment with CAGR ≈ -6% (2020–2024).
Arkema is divesting/restructuring these assets: announced exits and capex reductions totaling ~€120m through 2025 to refocus on low-GWP alternatives and sustainability-led growth.
Standard Acrylic Monomers
The commodity-grade acrylic monomers market faces global overcapacity—global MMA (methyl methacrylate) capacity exceeded demand by ~10% in 2024, driving price falls ~12% year-on-year and squeezing margins. Arkema’s footprint in standard, non-specialized monomers sits in the BCG Dogs quadrant with low growth and sub-5% EBITDA margins reported for the segment in 2024. Management has flagged rationalization options to redeploy €200–€300m capex toward higher-margin specialty acrylics and downstream formulations. These assets are prime candidates for exit or consolidation to boost group returns.
Low-Growth Regional Plasticizers
Certain regional plasticizer segments have become commoditized, with margins falling to single digits (EBIT margin ~4–6% in 2024) and prices down ~8% year‑on‑year due to local low‑cost competitors and tighter EU/US REACH and phthalate restrictions.
These units lost market share (Arkema regional volumes down ~5% in 2024) and generate low returns on capital, tying up ~€120–150m in working capital that could be redeployed to Advanced Materials.
Commodity Grade Resins
Commodity Grade Resins: basic PE/PP grades used in low-end packaging show low differentiation and high exposure to naphtha/ethane price swings; Arkema’s legacy commodity resins had single-digit EBITDA margins in 2024 and market share under 5% in key European thermoplastics segments.
These products face declining demand as customers shift to specialty polymers; revenue growth was near 0%–1% in 2023–24 and they typically break even, contributing negligible free cash flow while tying up capex.
- Low differentiation; high feedstock volatility
- Market share <5% in core segments (2024)
- Revenue growth ~0%–1% (2023–24)
- Single-digit EBITDA margins; often break even
Outdated Solvent-Based Technologies
Outdated solvent-based resin lines are classed as Dogs for Arkema as regulation and customer demand shift to water-borne and powder coatings; global solvent-borne coatings volumes fell ~6% CAGR 2019–2024, dragging market share below 5% in key EU and US segments.
Sales volumes for these resins dropped an estimated 18% from 2020–2024 within Arkema’s coatings portfolio, with gross margins near single digits due to idle capacity and high fixed costs.
Maintaining production for a shrinking base raises unit costs and capex intensity, so divestment or niche repositioning is financially preferable.
- Volume decline: ~18% (2020–2024)
- Market share: <5% in EU/US coatings
- Margins: ~single-digit gross margin
- Strategy: divest or niche reposition
Arkema "Dogs": low-share, declining commodity units — divest/restructure priority
Arkema Dogs: low-growth, low-share legacy commodities (legacy fluorogases, commodity acrylics, plasticizers, basic PE/PP, solvent-based resins) — market share <5% (2024); segment CAGR ≈ -6% (2020–24); single-digit EBITDA margins; tied-up capex/working capital ~€120–300m; divest/restructure priority.
| Segment | Share 2024 | CAGR 2020–24 | EBITDA 2024 | Redeploy € |
|---|---|---|---|---|
| Fluorogases | <5% | -6% | Low | 120 |
| Commodity acrylics | <5% | -6% | <5% | 200–300 |
| Plasticizers | <5% | -4% | 4–6% | — |
| Commodity resins | <5% | Single-digit | 120–150 |
Question Marks
Hydrogen Economy Membrane Materials
Arkema is investing in specialized ionomer membranes for PEM fuel cells and anion-exchange membranes for electrolyzers, targeting a market projected to reach $30–40 billion by 2030 (BloombergNEF, 2024) where membrane demand could grow >20% CAGR.
Today Arkema’s hydrogen membrane revenue is nascent—estimated under $50m in 2024—placing it as a Question Mark with single-digit market share against incumbents like 3M and Solvay.
Significant capex and R&D—Arkema signaled €100–150m scale programs in 2023–25—are needed to scale manufacturing, lower cost to <$50/kW equivalent membrane, and validate long-term durability.
If commercialization and partnerships accelerate over 2025–27, Arkema can seize rising electrolyzer deployments (120+ GW announced projects by 2025) but execution risk and incumbent competition remain high.
Molecular Recycling of Polymers
Arkema's Molecular Recycling of Polymers sits in Question Marks: it's targeting a >20% CAGR segment driven by 2025 EU/UK extended producer responsibility rules and global plastic-waste mandates; estimates show molecular recycling market ~USD 1.5–2.0 billion in 2024.
Tech is pre-commercial and net cash negative—pilot-to-demo scale needs ~€100–200m capex over 3–5 years; current units consume more cash than they earn, pressuring margins.
Strategic choice: double down with heavy internal investment to capture premium circular feedstock pricing (up to +30% vs virgin) or form industrial partnerships/JVs to share ~€150m deployment risk and speed commercialization.
Next-Generation Solid-State Battery Binders
Next-generation solid-state battery binders position Arkema as a Question Mark: the solid-state market is forecasted to grow at ~40% CAGR to reach $15–20B by 2030 (BloombergNEF 2025), but commercial production remains <5% of battery shipments in 2025. Arkema’s materials could capture high-margin share if it helps set standards now; failure to scale or lock partnerships would push heavy R&D spend without commensurate revenue.
3D Printing Specialty Materials
Arkema’s 3D printing specialty resins and powders sit in the Question Marks quadrant: the global additive manufacturing materials market was ~2.7 billion USD in 2024 and forecasted to reach ~5.1 billion by 2030 (CAGR ~10%), but Arkema competes with BASF, Evonik, and niche startups for share.
Converting R&D strength to scale is unresolved: Arkema reported €1.5 billion in Advanced Materials sales in 2024, yet additive-specific revenues remain a small mid-single-digit percent of that, keeping the business a strategic question mark.
- Market size 2024 ~2.7B USD; 2030 est ~5.1B USD
- Arkema Advanced Materials sales 2024 €1.5B
- Additive revenue = low single-digit % of segment
- Competition: BASF, Evonik, specialized startups
Bio-based Solutions for Medical Devices
Arkema’s bio-based polymers for surgical tools and implants sit in the Question Marks quadrant: high-growth niche but uncertain scale due to stringent regulation; global bioresorbable polymer market projected CAGR 12.5% to 2030, worth ~$1.9B in 2024 (source: industry reports).
Arkema has rolled out new high-performance grades in 2024 targeting orthopedic and disposables; capturing >5% market share will likely need 5–8 years of clinical trials and ~$30–50M in go-to-market spend to displace incumbents.
- High growth: 12.5% CAGR to 2030, $1.9B market 2024
- Regulatory lag: 5–8 years clinical validation
- Estimated investment: $30–50M marketing/clinical
- Short-term share target: <5% without partnerships
Arkema’s High-Risk, High-Reward Bets: H2 Membranes to Bioresorbables
Arkema’s Question Marks: hydrogen membranes (<$50m 2024 rev; €100–150m capex 2023–25), molecular recycling (~$1.5–2.0B market 2024; €100–200m scale capex), solid-state binders (market $15–20B by 2030), additive materials (~$2.7B market 2024), bioresorbables ($1.9B 2024; $30–50m go-to-market).
| Business | 2024 rev/market | Capex/needs |
|---|---|---|
| H2 membranes | <$50m | €100–150m |
| Molecular recycling | $1.5–2.0B | €100–200m |
| Solid-state binders | $15–20B est 2030 | Scale & partnerships |
| Additives | $2.7B | Increase share |
| Bioresorbables | $1.9B | $30–50m |